STERIS plc
$255.76+$1.00 (+0.4%)
Last close · Data as of Nov 20, 2026
- Market cap
- $20.7B
- P/E
- 26.5x
- EV / EBITDA
- 14.0x
- Revenue
- $5.9B
- Net margin
- 13.2%
- ROCE
- 11.5%
Price chart
Technical chartScreen technicals →-0.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +13.6%
- 3M
- +8.5%
- 6M
- +18.4%
- 1Y
- -0.5%
- 5Y
- +9.5%
52-week range
Day change +$1.00 (+0.4%) from $255 to $256 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in STE, bought on each weekday since 2021.
News & filings
What STERIS filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthNet profit grew 94.1% a year over three years.
Concerns
No concern stands out for this company on the data on file.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2026
Rule-based from financial data. Not advice.
About the company
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.
Read moreShow less
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
- Sector
- Healthcare
- Shares outstanding
- 98.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $20.7B
- P/E
- 26.5x
- P/B
- 2.9x
- EV / EBITDA
- 14.0x
- EV / Sales
- 3.8x
- P/S
- 3.5x
- 52-week high
- $268.65
- 52-week low
- $199.40
Profitability
- Operating margin
- 18.6%
- Net margin
- 13.2%
- EBITDA margin
- 26.9%
- ROE
- 10.9%
- ROCE
- 11.5%
- ROA
- 7.3%
- Asset turnover
- 0.55
Growth
- RevenueFY2026, the latest fiscal year in the company's growth history.
- $5.9B
- Revenue growth, 1YFY2026, the latest fiscal year in the company's growth history.
- 8.7%
- Revenue CAGR, 3YFY2026, the latest fiscal year in the company's growth history.
- 9.4%
- Net profit growth, 1YFY2026, the latest fiscal year in the company's growth history.
- 27.3%
- Free cash flowFY2026, the latest fiscal year in the company's growth history.
- $972.4M
Solvency
- Current ratio
- 2.09
- Debt / Equity
- 0.29
- Debt / Assets
- 0.19
- CFO / Net profit
- 1.71
- Cash / Market cap
- 2.1%
Where the revenue went
Of every $100 of FY2026 revenue, $13 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $3.3B |
| Revenue | Gross profit | $2.6B |
| Gross profit | Operating expenses | $1.5B |
| Gross profit | Operating income | $1.1B |
| Operating income | Pretax income | $1.0B |
| Operating income | Interest and other expense | $58.6M |
| Pretax income | Tax and other | $265.0M |
| Pretax income | Net income | $782.3M |
Revenue and net profit
Revenue grew 8.7% in FY2026; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2023 | $4.5B | $107.0M |
| FY2024 | $5.1B | $378.3M |
| FY2025 | $5.5B | $614.7M |
| FY2026 | $5.9B | $782.3M |
Cash flows
FY2026: $1.3B from operations, $972.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2023 | $756.9M | $395.0M |
| FY2024 | $973.3M | $613.0M |
| FY2025 | $1.1B | $778.0M |
| FY2026 | $1.3B | $972.4M |
Growth
Latest fiscal year 2026: each figure with its change over the year before.
- Revenue
- $5.9B+8.7%1Y
- EBITDA
- $1.6B+17.4%1Y
- Net profit
- $782.3M+27.3%1Y
- Cash from operations
- $1.3B+16.8%1Y
- Free cash flow
- $972.4M+25.0%1Y
- Revenue CAGR, 3Y
- 9.4%
- Net profit CAGR, 3Y
- 94.1%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2026 | $5.9B | $1.6B | $782.3M | $972.4M | 10.9% | +8.7% | +27.3% |
Monthly returns
Month-by-month returns of STE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2026.
| Line | FY2026 |
|---|---|
| Assets | $10.7B |
| Current assets | $2.4B |
| Non-current assets | $8.3B |
| Liabilities | $3.5B |
| Current liabilities | $1.1B |
| Non-current liabilities | $2.4B |
| Equity | $7.2B |
| Retained earnings | $3.0B |
| Minority interest | $13.6M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; STE highlighted.
P/E against peers
STE trades at 26.5x earnings against a peer median of 21.9x (a 21% premium).
Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| STERIS plcSTEthis companyP/E ↑ premium | $20.7B | 26.5x | 2.9x | 10.9% | 14.0x |
| Mettler-Toledo International Inc.MTD | $23.9B | 27.4x | — | -3676.8% | 20.9x |
| Insmed IncorporatedINSM | $22.7B | -17.8x | 30.8x | -172.8% | — |
| West Pharmaceutical Services, Inc.WST | $22.4B | 45.4x | 7.1x | 15.5% | 28.4x |
| Quest Diagnostics IncorporatedDGX | $21.7B | 21.9x | 3.0x | 13.8% | 12.9x |
| Labcorp Holdings Inc.LH | $21.4B | 24.4x | 2.5x | 10.2% | 13.6x |
| Moderna, Inc.MRNA | $20.5B | -7.3x | 2.4x | -32.6% | -7.5x |
| Incyte CorporationINCY | $20.2B | 15.7x | 3.9x | 24.9% | 9.8x |
| Viatris Inc.VTRS | $18.5B | — | 1.3x | -23.9% | — |
| Peer median | — | 21.9x | 3.0x | -6.9% | 13.2x |
Year-to-date ROI
STE since 1 January, against earlier years.
Historical volatility
STE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2023 | 17.5% |
| FY2024 | 16.8% |
| FY2025 | 17.6% |
| FY2026 | 18.6% |
| Line | FY2026 |
|---|---|
| RevenueTotal Revenue | $5.9B |
| Cost of revenueCost Of Revenue | $3.3B |
| Gross profitGross Profit | $2.6B |
| Operating expensesOperating Expense | $1.5B |
| Research and developmentResearch And Development | $112.9M |
| Selling, general and administrativeSelling General And Administration | $1.4B |
| Total expensesTotal Expenses | $4.8B |
| Operating incomeOperating Income | $1.1B |
| Interest and other | |
| Pretax incomePretax Income | $1.0B |
| TaxTax Provision | $262.2M |
| Net incomeNet Income | $782.3M |
| Per share | |
| Supplementary |
| Line | FY2026 |
|---|---|
| AssetsTotal Assets | $10.7B |
| Current assetsCurrent Assets | $2.4B |
| Non-current assetsTotal Non Current Assets | $8.3B |
| LiabilitiesTotal Liabilities Net Minority Interest | $3.5B |
| Current liabilitiesCurrent Liabilities | $1.1B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $2.4B |
| EquityTotal Equity Gross Minority Interest | $7.2B |
| Supplementary |
| Line | FY2026 |
|---|---|
| Operating cash flowOperating Cash Flow | $1.3B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $1.3B |
| Net income, continuing operationsNet Income From Continuing Operations | $785.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $486.5M |
| Stock-based compensationStock Based Compensation | $61.7M |
| Deferred taxDeferred Tax | -$16.9M |
| Deferred income taxDeferred Income Tax | -$16.9M |
| Operating gains and lossesOperating Gains Losses | $3.3M |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $3.6M |
| Gain loss on sale of businessGain Loss On Sale Of Business | -$300.0k |
| Asset impairmentAsset Impairment Charge | — |
| Change in working capitalChange In Working Capital | $27.1M |
| Other non-cash itemsOther Non Cash Items | -$5.4M |
| Investing cash flowInvesting Cash Flow | -$512.5M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$512.6M |
| Capital expenditureCapital Expenditure | -$369.0M |
| Purchase of PP&EPurchase Of PPE | -$369.0M |
| Sale of PP&ESale Of PPE | $10.5M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$358.5M |
| AcquisitionsPurchase Of Business | -$20.1M |
| DisposalsSale Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$20.1M |
| Purchase of investmentsPurchase Of Investment | -$134.0M |
| Sale of investmentsSale Of Investment | $0.00 |
| Net investment purchases and salesNet Investment Purchase And Sale | -$134.0M |
| Other investing changesNet Other Investing Changes | $100.0k |
| Financing cash flowFinancing Cash Flow | -$568.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$568.2M |
| Debt issuedIssuance Of Debt | $3.0M |
| Debt repaidRepayment Of Debt | -$125.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$122.0M |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt issuedLong Term Debt Issuance | $3.0M |
| Long-term debt repaidLong Term Debt Payments | -$125.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$122.0M |
| Net common stock issuedNet Common Stock Issuance | -$235.5M |
| Common stock repurchasedCommon Stock Payments | -$235.5M |
| Share buybacksRepurchase Of Capital Stock | -$235.5M |
| Stock options exercisedProceeds From Stock Option Exercised | $32.9M |
| Dividends paidCash Dividends Paid | -$241.8M |
| Common dividends paidCommon Stock Dividend Paid | -$241.8M |
| Other financing chargesNet Other Financing Charges | -$1.8M |
| Change in cashChanges In Cash | $260.7M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 720.0% |
| Cash at the start of the yearBeginning Cash Position | $171.7M |
| Cash at the end of the yearEnd Cash Position | $439.6M |
| Free cash flowFree Cash Flow | $972.4M |
| Supplemental |
Learn while you research
Academy chapters picked for STERIS plc and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read